Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

B72.3 is a murine monoclonal antibody (IgG1) that recognizes a tumor-associated glycoprotein, termed TAG-72. B72.3 has been shown, using a variety of methodologies, to have a high degree of selective reactivity for colorectal, ovarian, lung, and breast carcinomas. Radiolabeled B72.3 has been administered both i.v. and i.p. in patients with colorectal and ovarian cancer as well as other carcinomas and has been shown to selectively bind to approximately 70-80% of metastatic lesions. Greater than 50% of the patients that have been treated with B72.3 have developed an immunological response to murine IgG after a single injection. In an attempt to minimize the immune response of these patients to the administered murine monoclonal antibody, we developed a recombinant form of the murine B72.3 as well as a recombinant/chimeric antibody, using the variable regions of the murine B72.3 and human heavy chain (gamma 4) and light chain (kappa) constant regions. We report here that both the recombinant B72.3 [rB72.3] and the recombinant/chimeric B72.3 [cB72.3(gamma 4)] IgGs maintain the tissue binding and idiotypic specificity of the native murine IgG. The native B72.3, rB72.3, and cB72.3(gamma 4) IgGs were radiolabeled and the biodistribution of these IgGs was studied in athymic mice bearing human colon carcinoma xenografts (LS-174T). Differences were observed between the cB72.3(gamma 4) and the native B72.3 in the percentage of injected dose/g that localized in the tumor. The somewhat lower absolute amounts of the cB72.3(gamma 4) in the tumor are mostly likely due to the observed more rapid clearance from the blood and body of the mouse as compared to the native B72.3 and rB72.3. All three forms [native B72.3, rB72.3, and cB72.3(gamma 4)] of the IgG, however, were able to localize the colon tumor with similar radiolocalization indices [percentage of injected dose/g in tumor divided by the percentage of injected dose/g in normal tissue].

[1]  S. Jewell,et al.  Intraoperative radioimmunolocalization of colorectal carcinoma with a hand‐held gamma probe and MAb B72.3: Comparison of in vivo gamma probe counts with in vitro MAb radiolocalization , 1988, International journal of cancer.

[2]  M. Kuroki,et al.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. , 1988, Cancer research.

[3]  J. Ghrayeb,et al.  Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. E. Simpson,et al.  Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  J. Ghrayeb,et al.  Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody. , 1988, Journal of biological response modifiers.

[6]  J. Schlom,et al.  Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody. , 1988, Radiology.

[7]  J. Schlom,et al.  Complementation of anti‐CEA and anti‐TAG‐72 monoclonal antibodies in reactivity to human gastric adenocarcinomas , 1987, International journal of cancer.

[8]  R. R. Robinson,et al.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.

[9]  J. Schlom,et al.  Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors , 1987, Diseases of the colon and rectum.

[10]  M. Salvatore,et al.  Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum , 1987, Diseases of the colon and rectum.

[11]  A. Thor,et al.  Monoclonal Antibody B72.3 Reactivity with Human Endometrium: A Study of Normal and Malignant Tissues , 1987, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[12]  S. Larson,et al.  Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. , 1987, Cancer research.

[13]  M. Ho,et al.  Tumor-specific genetically engineered murine/human chimeric monoclonal antibody. , 1987, Cancer research.

[14]  R. R. Robinson,et al.  Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Larson,et al.  Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. , 1987, Cancer research.

[16]  R. Ueda,et al.  Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. , 1987, Cancer research.

[17]  S. Larson,et al.  Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3 , 1987, International journal of cancer.

[18]  M. Larché,et al.  Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. , 1986, Cancer research.

[19]  J. Ghrayeb,et al.  Chimeric antibodies with 17-1A-derived variable and human constant regions. , 1986, Hybridoma.

[20]  A. Thor,et al.  Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. , 1986, Journal of the National Cancer Institute.

[21]  A. Thor,et al.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.

[22]  J. Schlom,et al.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. , 1986, Cancer research.

[23]  S. Morrison.  Transfectomas provide novel chimeric antibodies. , 1985, Science.

[24]  L. M. Smith,et al.  Human immune response to multiple injections of murine monoclonal IgG. , 1985, Journal of immunology.

[25]  R. L. Childs,et al.  Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[27]  S. Larson,et al.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.

[28]  C. Mulhern,et al.  Detection of metastatic tumor in normal-sized retroperitoneal lymph nodes by monoclonal-antibody imaging. , 1984, The New England journal of medicine.

[29]  J. Douillard,et al.  Immunoscintigraphy of colon carcinoma. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[31]  C. Mulhern,et al.  Metastatic colon carcinoma detected with radiolabeled F(ab')2 monoclonal antibody fragments. , 1983, Radiology.

[32]  J. Schlom,et al.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas , 1983, International journal of cancer.

[33]  R. Mariani-Costantini,et al.  A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations , 1982, International journal of cancer.

[34]  M. Forni,et al.  Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. , 1981, Immunology today.

[35]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J R van Nagell,et al.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. , 1978, The New England journal of medicine.

[37]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[38]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[39]  T. Puck,et al.  GENETICS OF SOMATIC MAMMALIAN CELLS III. LONG-TERM CULTIVATION OF EUPLOID CELLS FROM HUMAN AND ANIMAL SUBJECTS , 1958 .

[40]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[41]  B. Sahagan.  A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. , 1990, Journal of immunology.

[42]  横山 正俊.  Suppression of tumor growth by in vivo administration of a recombinant human-mouse chimeric monoclonal antibody , 1988 .

[43]  J. Schlom,et al.  Expression in COS cells of a mouse-human chimaeric B72.3 antibody. , 1987, Protein engineering.

[44]  R. Levy,et al.  Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. , 1983, Blood.

[45]  U. K. Laemmli,et al.  Cleavage of structural proteins during , 1970 .